This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC
Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC
An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Savolitinib Combo Prolongs PFS in Pretreated EGFR+ NSCLC
Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.
HER3-DXd Does Not Yield Improved OS in EGFR-Mutated NSCLC
Results from HERTHENA-Lung02 did not show improved OS with HER3-DXd for patients with EGFR-mutated NSCLC.